Clinical trial of amodiaquine in Attecoube (Abidjan, Cote d'Ivoire) (May-December 1995)

A prospective study in the municipality of Attecoube (Abidjan, Cote d'Ivoir e) evaluated the sensitivity of P. falciparum to amodiaquine with a posolog y of 35 mg/kg over 3 days (1st day.- 15 mg/kg, 2nd day: 10 mg/kg; 3rd day: 10 mg/kg) as well as its tolerance of this dosage. One hundred five WHO in vivo standard tests were performed over 7 clays on subjects aged > 15 years from May to December 1995. The subjects were carri ers of varying number of trophozoites: between 1000 to 34 000 trophozoites were recorded with a mean of 5193 trophozoites by microliter. We divided th e subjects into two groups: group A with 43 patients to whom we administere d medication and group B with 62 subjects who took their medication on thei r own. Clinical and parasitological verifications were made on D0, D2 and D 7. Biological verification was conducted for 31 subjects of group A by mean of SGOT and SGPT quantity determination on D0 and D2. This survey revealed that 1,9 % of P. falciparum malaria patients had preco cious therapeutic failure to amodiaquine (35 mg/kg over 3 days) in this are a. Clinical and biological tolerance was good and there was no difference b etween the two groups. We suggest that amodiaquine might be used for uncomplicated malaria at firs t intention in Abidjan.